Head-to-Head

Generate Biomedicines, Inc. Common Stock vs. Eli Lilly & Co.

GENB

Generate Biomedicines, Inc. Common Stock

$16.14 -20.80%

VS LLY

Eli Lilly & Co.

$1189.41 -3.59%

Generate Biomedicines, Inc. Common Stock (GENB) comes out ahead, leading on 2 of 3 compared factors.

Size & Scale

GENBLLY
Market Cap $2.62 billion $1.10 trillion
Revenue (TTM) — $79.67 billion
Net Income (TTM) — $26.71 billion

LLY leads on 1 of 1 size & scale factors.

Valuation

GENBLLY
P/E Ratio — 39.93
Price / Book 5.74 32.46
Price / Sales — 13.80

GENB leads on 1 of 1 valuation factors.

Profitability

GENBLLY
Net Margin — 33.53%
Return on Equity — 78.84%

GENB and LLY split the profitability factors evenly.

Dividend

GENBLLY
Dividend Yield — 0.58%
Payout Ratio — 23.23

GENB and LLY split the dividend factors evenly.

Risk & Sentiment

GENBLLY
Short Interest 0.70% 1.29%

GENB leads on 1 of 1 risk & sentiment factors.

Dig deeper: GENB overview, GENB financials, LLY overview, LLY financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.